Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 600.2%

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Approximately 4.4% of the shares of the stock are short sold. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is presently 0.3 days.

Xilio Therapeutics Trading Down 4.7 %

Shares of NASDAQ XLO opened at $1.01 on Friday. The stock has a market cap of $34.81 million, a price-to-earnings ratio of -0.36 and a beta of -0.12. The stock’s 50-day moving average is $0.91 and its 200 day moving average is $1.03. Xilio Therapeutics has a 1-year low of $0.49 and a 1-year high of $3.40.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.64) earnings per share for the quarter. On average, analysts forecast that Xilio Therapeutics will post -1.53 EPS for the current fiscal year.

Insider Buying and Selling at Xilio Therapeutics

In other Xilio Therapeutics news, major shareholder Gilead Sciences, Inc. bought 485,250 shares of the firm’s stock in a transaction on Tuesday, April 2nd. The shares were acquired at an average cost of $0.76 per share, for a total transaction of $368,790.00. Following the purchase, the insider now directly owns 7,345,473 shares of the company’s stock, valued at $5,582,559.48. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Xilio Therapeutics stock. PFG Investments LLC bought a new position in Xilio Therapeutics, Inc. (NASDAQ:XLO) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 30,000 shares of the company’s stock, valued at approximately $32,000. PFG Investments LLC owned 0.09% of Xilio Therapeutics as of its most recent SEC filing. 54.29% of the stock is currently owned by institutional investors.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors.